Related Experiment Videos
Serum lipoprotein changes during atenolol treatment of essential hypertension
Insights
Atenolol treatment effectively lowers blood pressure but can increase triglycerides, leading to hypertriglyceridemia in some patients. This lipid change poses a risk for atherosclerosis despite blood pressure control.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Biochemistry
Background:
- Antihypertensive medications are crucial for managing high blood pressure.
- Long-term effects of specific antihypertensives on lipid profiles require ongoing investigation.
- Atenolol is a commonly prescribed beta-blocker for hypertension.
Purpose of the Study:
- To investigate the impact of atenolol on serum lipoprotein levels in hypertensive patients.
- To assess the development of dyslipidemia during atenolol therapy.
- To correlate blood pressure changes with alterations in lipid metabolism.
Main Methods:
- Serum lipoprotein analysis was performed on 15 patients before and during atenolol treatment.
- Blood pressure was monitored throughout the study period.
- Lipid parameters, including very low density lipoprotein triglycerides (VLDL-TG) and low density lipoprotein triglycerides (LDL-TG), were quantified.
Main Results:
- Atenolol treatment significantly reduced mean blood pressure.
- Significant increases in VLDL-TG and LDL-TG were observed.
- Hypertriglyceridemia developed in 7 out of 15 patients during atenolol therapy.
- No significant changes were noted in total serum cholesterol or high density lipoprotein cholesterol.
Conclusions:
- Long-term atenolol treatment can lead to hypertriglyceridemia in a subset of hypertensive patients.
- The benefits of normotension may be offset by an increased risk of hypertriglyceridemia.
- Hypertriglyceridemia is a known risk factor for atherosclerosis, necessitating careful monitoring of lipid profiles in patients on atenolol.
Abstract:
Serum lipoproteins were determined in 15 patients before and during antihypertensive treatment with atenolol (0.1-0.2 g/day for a mean of 8 months. The mean blood pressure fell from 171/103 to 154/93 mm Hg (p less than 0.05). Significant lipoprotein changes were an increase in very low density triglycerides (VLDL-TG) from 1.21 +/- 0.95 (SD) to 1.62 +/- 1.24 mmol/l (p less than 0.01) and in low density (LDL) TG from 0.46 +/- 0.12 to 0.51 +/- 0.12 mmol/l (p less than 0.05). Together, these TG increases resulted in development of hypertriglyceridaemia in 7/15 patients during atenolol treatment. No effect on whole serum cholesterol or on the high density lipoprotein cholesterol concentrations were found. Thus, some patients on long term treatment with atenolol seem to received the benefit of normotension at the cost of hypertriglyceridaemia. This may have practical implications, since hypertriglyceridaemia, constitutes an important risk factor for atherosclerosis.